Market Overview - The Hong Kong stock market showed a narrowing upward trend, with the Hang Seng Index and the Hang Seng China Enterprises Index closing at 26,848 points and 9,285 points, up 0.9% and 0.7% respectively, indicating sustained investor confidence as the total turnover reached HKD 315.2 billion, slightly higher than the previous day's HKD 306.2 billion [1] - In sector performance, materials, energy, and healthcare indices rose by 1.9%, 1.6%, and 1.6% respectively, while consumer staples, telecommunications, and information technology sectors saw declines of 0.4%, 0.3%, and 0.1% [1] Real Estate Sector - The Hong Kong real estate sector continued its upward trend, with major companies such as Henderson Land (12 HK), Sun Hung Kai Properties (16 HK), and New World Development (17 HK) rising by 3.0%, 1.2%, and 7.2% respectively [2] - Recent adjustments in housing price forecasts by financial institutions support the view of an improving real estate market, driven by declining interest rates and a projected decrease in new housing supply [2] - The anticipated government announcement at the end of January regarding new housing supply statistics for 2025 is expected to further confirm this trend, with a projected 61.9% year-on-year decrease in private residential construction units for the first three quarters of 2025 [2] Macro Dynamics - The U.S. Consumer Price Index (CPI) for December showed a year-on-year growth of 2.7%, consistent with November's figure and market expectations [3] Automotive Sector - The automotive sector is experiencing changes due to a government announcement that will reduce battery export tax rebates from 9% to 6% starting in April, with a complete elimination by 2027, prompting downstream battery manufacturers to accelerate production and order placements [4] - This policy is expected to lead to a short-term surge in demand for lithium resources, with companies like CATL (3750 HK), Tianqi Lithium (9696 HK), Ganfeng Lithium (1772 HK), and BYD (1211 HK) showing stock price increases of 0.9%, 0.8%, 3.9%, and 1.6% respectively [4] Healthcare Sector - The Hang Seng Healthcare Index rose by 1.7%, with WuXi AppTec (2359 HK) announcing a positive earnings forecast, projecting a 15.8% year-on-year revenue increase to RMB 45.46 billion and a 102.7% increase in net profit to RMB 19.15 billion for 2025 [5] - WuXi AppTec's core business profitability, as measured by Non-IFRS adjusted net profit, is expected to rise by 41.3% to RMB 14.96 billion, exceeding Bloomberg's forecasts, which contributed to an 8.3% increase in its stock price [5] - WuXi Biologics (2269 HK) is also expected to report strong 2025 results, while Rongchang Biologics (9995 HK) signed an exclusive licensing agreement with AbbVie (ABBV US) for its new PD-1/VEGF dual-specific antibody drug, RC148, which includes an upfront payment of USD 650 million and potential milestone payments of up to USD 4.95 billion [5] Energy Sector - The new energy and utilities sectors displayed mixed performance, lacking significant new developments, while the thermal power sector generally rose, benefiting from stable coal prices despite colder weather in some regions [6] - Companies such as Huaneng International (902 HK), Datang International (991 HK), and Huadian International (1071 HK) saw stock price increases ranging from 1.4% to 2.2% [6]

该行仍对该公司在整体生物制剂外包市场中获得市占率，并赢得更多商业项目的能力充满信心。并相信 其先进的生物制造技术平台，使其能够良好地把握未来对先进全规模连续生物工艺需求增长的机遇。小 摩预测药明生物2025、2026年预估收入将分别增长至213亿元、246亿元人民币，同比增长率分别为14% 及15%。 摩根大通发布研报称，维持药明生物(02269)增持评级。药明生物计划在今日(14日)的第44届摩根大通医 疗健康大会上展示，当中所列出正在进行中的项目数量超出了该行预期，并将几个营运亮点视为正面， 包括公司正顺利实现强劲的2025年营收和盈利增长、去年完成了28项PPQ(工艺性能确认)，并计划在今 年完成34项等，预计这些数据点将支持公司今年持续增长。 ...

智通财经APP获悉，摩根大通发布研报称，维持药明生物(02269)增持评级。药明生物计划在今日(14日) 的第44届摩根大通医疗健康大会上展示，当中所列出正在进行中的项目数量超出了该行预期，并将几个 营运亮点视为正面，包括公司正顺利实现强劲的2025年营收和盈利增长、去年完成了28项PPQ(工艺性 能确认)，并计划在今年完成34项等，预计这些数据点将支持公司今年持续增长。 该行仍对该公司在整体生物制剂外包市场中获得市占率，并赢得更多商业项目的能力充满信心。并相信 其先进的生物制造技术平台，使其能够良好地把握未来对先进全规模连续生物工艺需求增长的机遇。小 摩预测药明生物2025、2026年预估收入将分别增长至213亿元、246亿元人民币，同比增长率分别为14% 及15%。 ...

Macro Economy - The Ministry of Industry and Information Technology (MIIT) issued an action plan for the high-quality development of industrial internet platforms from 2026 to 2028, aiming to have over 450 influential platforms and more than 120 million industrial devices connected by 2028, with a platform penetration rate exceeding 55% [2] - MIIT held the 18th manufacturing enterprise symposium, emphasizing active participation in industry rule-making and self-regulation to promote a win-win environment and protect industry development [2] Investment News - On January 13, A-shares experienced a collective pullback, with the Shanghai Composite Index ending a 17-day winning streak, closing down 0.64%. The total trading volume in Shanghai, Shenzhen, and Beijing reached 3.7 trillion, setting a new historical record [5] - The Hang Seng Index rose by 0.9%, with the Hang Seng Technology Index increasing by 0.11%. Pharmaceutical stocks performed well, with WuXi AppTec rising over 8% and WuXi Biologics nearly 6%. The H-share listing of Zhaoyi Innovation saw a peak increase of over 53% on its first day, closing with a 37.53% rise, valuing the company at 155.2 billion HKD [5] - As of January 12, the management scale of ETF products under Huaxia Fund officially surpassed 1 trillion RMB, reaching 1,016.424 billion RMB, making it the first domestic ETF manager to enter the "trillion club" [5] - Approximately 130 A-share listed companies have disclosed their 2025 performance forecasts, with around 70 companies expecting positive results, including profit increases and recoveries [5] - A total of 186 listed companies have been subject to concentrated research by public funds and brokerages, with the number of research instances reaching 220, indicating strong interest in popular stocks like Aipeng Medical and Entropy Technology [5] Company Movements - Guizhou Moutai is establishing a dynamic adjustment mechanism for retail prices based on market orientation, aiming for a "market-following, relatively stable" self-operated system [6] - The "Dead or Alive APP" will officially adopt the global brand name Demumu in its upcoming new version [7] - Alibaba Cloud has completed further strategic investment in ZStack, achieving a controlling stake, and plans to create a standardized and inclusive cloud-edge integrated solution [7] - DeepSeek published a new paper on conditional memory for large language models, co-authored with Peking University [7] - Huaxia Happiness expects a net loss of 16 billion to 24 billion RMB in 2025, with potential delisting risk warnings for its stock [8] - Zhongwen Online anticipates a net loss of 580 million to 700 million RMB in 2025, as its overseas short drama business is still in the investment phase [8] - Luxshare Precision has terminated its acquisition of the business asset package held by India's Wingtech [8]

Core Viewpoint - The southbound capital flow into the Hong Kong stock market reached a record net inflow of 1,404.844 billion HKD in 2025, continuing into 2026 with a cumulative net inflow of 41.296 billion HKD as of January 13, 2026, indicating strong market performance driven by this influx [1][2]. Group 1: Southbound Capital Flow - In 2025, southbound capital became the largest source of incremental funds for the Hong Kong stock market, with a total net inflow of 1,404.844 billion HKD, setting a record for annual net inflow [2]. - As of January 13, 2026, there were 6 out of 7 trading days with net inflows, totaling 41.296 billion HKD since the beginning of the year [2]. - The number of shares held by southbound capital increased to 5,643.75 billion shares, with a market value of 6.33 trillion HKD, reflecting a growth of 0.19 trillion HKD since the start of 2026 [2]. Group 2: Market Performance - The Hang Seng Index rose over 4% and the Hang Seng Technology Index increased over 6% since the beginning of 2026, with more than 60% of stocks in the index with a market capitalization exceeding 1 trillion HKD showing an average increase of over 3% [1][5]. - The healthcare, materials, and conglomerates sectors led the market with increases of 15.46%, 12.86%, and 7.62% respectively, while only the telecommunications sector saw a decline of 0.49% [5][6]. - Major stocks such as Tencent Holdings and Alibaba-W saw significant increases, with Tencent rising 4.76% and Alibaba increasing 11.97% since the start of 2026 [6]. Group 3: Investment Outlook - Analysts predict that the southbound capital flow will continue to increase, driven by the low allocation of mainland investors in Hong Kong stocks and the trend of retail funds flowing into the market through ETFs [4]. - The market is expected to benefit from the "14th Five-Year Plan" and the dual easing of fiscal and monetary policies from major economies, with a focus on technology innovation and consumption themes [7][8]. - Five long-term investment directions are suggested: technology sectors including AI, healthcare, resource sectors benefiting from inflation, essential consumer sectors, and industries benefiting from RMB appreciation [8].

Core Insights - The article provides an overview of the latest performance of various mutual funds, highlighting the top and bottom performers based on net asset value changes [1]. Fund Performance Summary Top Performing Funds - The top 10 funds with the highest net value growth include: 1. Guotou Ruijin Silver Futures (LOF) A: 2.3777, up 6.27% 2. Xinao Medical Health Mixed A: 1.3136, up 4.78% 3. Xinao Medical Health Mixed C: 1.3101, up 4.77% 4. GF Innovation Medical Two-Year Holding Mixed C: 0.9070, up 4.61% 5. GF Innovation Medical Two-Year Holding Mixed A: 0.9245, up 4.61% 6. Wanjia Global Growth One-Year Holding Mixed (QDII) C: 0.9410, up 4.34% 7. Wanjia Global Growth One-Year Holding Mixed (QDII) A: 0.9656, up 4.33% 8. Xinao Enjoy Life Mixed C: 1.2091, up 4.29% 9. Xinao Enjoy Life Mixed A: 1.2301, up 4.28% 10. GF Hong Kong-Shanghai Medical Mixed A: 1.1561, up 4.26% [2][3]. Bottom Performing Funds - The bottom 10 funds with the largest declines in net value include: 1. Dongfang Alpha Zhaoyang Mixed A: 0.5213, down 6.36% 2. Dongfang Alpha Zhaoyang Mixed E: 0.5144, down 6.35% 3. Great Wall Prosperity Growth Mixed C: 1.6053, down 6.22% 4. Great Wall Prosperity Growth Mixed A: 1.6280, down 6.22% 5. Xinyuan Industry Opportunity Mixed A: 1.1447, down 6.06% 6. Xinyuan Industry Opportunity Mixed C: 1.1432, down 6.06% 7. Huaan Big Security Theme Mixed C: 3.0600, down 5.99% 8. Huaan Big Security Theme Mixed A: 3.1370, down 5.97% 9. Zhongou High-end Equipment Stock Initiation C: 1.1549, down 5.79% 10. Zhongou High-end Equipment Stock Initiation A: 1.1731, down 5.79% [3]. Market Overview - The Shanghai Composite Index opened high but experienced wide fluctuations, closing with a small decline. The total trading volume reached 3.69 trillion, with a ratio of advancing to declining stocks at 1622:3729 [5]. - The leading sectors included insurance, which rose over 2%, while the lagging sectors were aviation, semiconductors, and telecommunications, which fell over 3% [5].

Market Overview - On January 13, the Hang Seng Index rose by 0.90%, with total southbound trading amounting to HKD 137.35 billion, including buy transactions of HKD 69.32 billion and sell transactions of HKD 68.03 billion, resulting in a net buying amount of HKD 1.30 billion [1] Southbound Trading Activity - The southbound trading through Stock Connect (Shenzhen) recorded a total trading amount of HKD 54.86 billion, with buy transactions of HKD 28.00 billion and sell transactions of HKD 26.85 billion, leading to a net buying amount of HKD 1.15 billion [1] - The southbound trading through Stock Connect (Shanghai) had a total trading amount of HKD 82.49 billion, with buy transactions of HKD 41.32 billion and sell transactions of HKD 41.17 billion, resulting in a net buying amount of HKD 0.15 billion [1] Active Stocks - Alibaba-W was the most actively traded stock with a total trading amount of HKD 139.06 billion and a net buying amount of HKD 10.71 billion, closing with a price increase of 3.63% [1][2] - Tencent Holdings followed with a total trading amount of HKD 52.93 billion and a net buying amount of HKD 7.56 billion, closing with a price increase of 0.72% [1][2] - Xiaomi Group-W had a total trading amount of HKD 49.62 billion and a net buying amount of HKD 6.07 billion, closing with a price decrease of 1.96% [1][2] Continuous Net Buying and Selling - Three stocks experienced continuous net buying for more than three days, with Xiaomi Group-W, Tencent Holdings, and Kuaishou-W having net buying days of 9, 5, and 3 respectively [2] - Tencent Holdings had the highest cumulative net buying amount of HKD 69.99 billion, followed closely by Xiaomi Group-W with HKD 69.33 billion [2] - Two stocks faced continuous net selling, with China Mobile and Meituan-W having net selling amounts of HKD 52.84 billion and HKD 11.67 billion respectively [2]

Core Viewpoint - The article discusses the evolving landscape of the Chinese healthcare sector, particularly in the context of the upcoming JP Morgan Healthcare Conference, highlighting the diversification of Chinese companies and their strategic positioning in the global market [4][29]. Group 1: Conference Overview - The JP Morgan Healthcare Conference is the largest and most informative international healthcare investment and business development meeting, scheduled for January 12-15, 2026, in San Francisco [4]. - Approximately 22 Chinese companies are participating, categorized into four distinct roles: transaction-oriented innovative drug companies, disclosure companies at commercialization or regulatory milestones, supply-side platforms for global R&D and production outsourcing, and device companies focusing on efficiency and international expansion [4]. Group 2: Supply-Side Platforms - Supply-side platform companies are becoming essential in the global innovation chain, as they focus on delivering stable and efficient R&D and production capabilities, especially during periods of increased volatility in innovative drug companies [6][8]. - WuXi Biologics is shifting its focus from project quantity to project quality, emphasizing capacity utilization and long-term contract stability as key indicators of its value in the global biopharmaceutical supply chain [8]. Group 3: Cross-Border Licensing and Outbound Companies - The pricing logic for Chinese innovative drugs in cross-border licensing has evolved, with a focus on the overall deliverable capabilities rather than just the individual molecules [14]. - Companies like Kelun-Blotech and BaiLi Tianheng are exemplifying this trend by integrating their platforms into global R&D systems and establishing long-term collaborations with multinational pharmaceutical companies [16][18]. Group 4: Regulatory and Commercialization Companies - Companies that have accumulated clinical data and registration progress are transitioning towards verifiable sales and profit curves, shifting their valuation logic from future expectations to tangible cash flows [19]. - Zai Lab and Antengene are in the early commercialization stages, with their success hinging on their products' acceptance in clinical settings and the speed of prescription growth [21][23]. Group 5: Medical Device Companies - Mindray Medical is recognized for its comprehensive coverage of hospital workflows, with a focus on multi-product synergy rather than single-device performance, which is crucial for establishing long-term customer relationships [26]. - MicroPort Scientific is navigating a challenging environment where operational efficiency and cash flow management are critical for sustaining long-term clinical validation and international expansion [28]. Group 6: Industry Trends and Insights - The Chinese healthcare sector is transitioning from a phase of visibility to one of selection, where companies must clearly define their positions and deliverables in a high-intensity global exchange [29]. - The differentiation among Chinese companies in the global system is accelerating, with a clear divide between transaction-oriented innovative drug companies and those that have crossed critical regulatory milestones, focusing on verifiable growth [31].

Market Overview - The A-share market has experienced a correction after continuous growth, while the Hong Kong stock market showed signs of catching up, opening with a gap and closing up 0.90% with a trading volume of HKD 315.2 billion [1] - The AI sector is gaining significant attention, with Alibaba's Tongyi Qianwen series models achieving over 700 million downloads, making it the highest downloaded open-source AI series on the Hugging Face platform [1] - Concerns remain in the market due to geopolitical tensions, particularly with the U.S. urging citizens to leave Iran, which has affected investor sentiment [1] AI Sector - Several domestic AI companies, including MiniMax and Zhipu AI, have recently gone public in Hong Kong, attracting market interest, with the latest listing of Zhaoyi Innovation seeing a rise of over 40% [2] - Despite recent adjustments in the AI sector, the overall interest in high-tech companies remains strong [2] Pharmaceutical and Biotechnology - Merck's CEO indicated plans for aggressive acquisitions to strengthen its innovative drug pipeline before the expiration of the patent for Keytruda in 2028, which is positive news for Chinese innovative drug companies [3] - WuXi Biologics reported record high upfront and total payment amounts for research services, with potential milestone payments exceeding USD 4 billion, leading to a positive outlook for CXO companies [3] Commercial Aerospace - A number of companies in the commercial aerospace sector issued risk warnings, indicating that their aerospace business constitutes a minimal portion of their operations, with most being less than 1% [2] - Regulatory efforts appear to be aimed at cooling down the commercial aerospace hype, as evidenced by a nearly 10% drop in shares of Goldwind Technology [2] Renewable Energy and Storage - The domestic energy storage market saw a significant increase in bidding volume, with a year-on-year growth of 61% in new bidding capacity [5] - Companies like Guofeng Lithium and Tianqi Lithium have performed well, driven by market expectations for increased demand in the short term due to policy changes regarding export tax rebates for photovoltaic and battery products [4] Gold and Mining - Zijin Mining International's stock rose over 7% as gold prices reached new highs, supported by rising risk aversion among investors [7] - The company has a significant amount of gold resources and a low average acquisition cost for gold mines, which positions it favorably for future growth [8] - The company’s gold production is expected to maintain a compound annual growth rate (CAGR) of over 15% through 2025-2027, driven by both internal growth and acquisitions [8]

Core Viewpoint - Biomanufacturing is identified as a key future industry in China's 14th Five-Year Plan, expected to create a market worth trillions in the next decade, driven by advancements in technology and policy support [2][5]. Group 1: Industry Overview - The biomanufacturing industry in China is nearing a total scale of 1 trillion yuan, with fermentation capacity accounting for over 70% of the global total [2][4]. - Shenzhen has become a hub for biomanufacturing, with 40% of newly established companies in this sector located there in the past three years, showcasing a significant industry clustering effect [4]. - The industry is supported by a comprehensive system of policy, funding, and technological advancements as outlined in the 14th Five-Year Plan [5]. Group 2: Key Enterprises - The article identifies 100 core enterprises in biomanufacturing, spanning the entire industry chain from upstream technology development to downstream commercial applications [7]. - Notable companies include: - Huada Technology, a leader in gene sequencing technology [17]. - Kaisa Biotech, which has achieved over 80% market share in the global long-chain dicarboxylic acid market [21]. - WuXi Biologics, representing China's capabilities in the global biopharmaceutical industry [27]. Group 3: Upstream Innovations - The upstream sector focuses on providing essential tools and technologies for research and production, with a shift towards domestic innovation and smart integration [16]. - Key trends include the localization of critical tools and the rise of AI-driven platform companies that enhance research efficiency [16][17]. - Over 75% of the 20 identified upstream enterprises are private, indicating a vibrant innovation landscape [16]. Group 4: Midstream Developments - The midstream sector is characterized by a dual structure of "upgraders" and "disruptors," with companies like Meihua Biotech and Chuaning Biotech leading in traditional fermentation while others like Kaisa Biotech innovate with new bioproducts [20][21]. - This segment contains the highest number of enterprises, with 40 out of the 100 identified companies, emphasizing the importance of production capacity and cost control [20]. Group 5: Downstream Applications - The downstream sector serves as a critical market for biomanufacturing, focusing on medical, consumer, and agricultural applications [25]. - Companies like Muyuan Foods exemplify the cost-saving potential of biomanufacturing in agriculture, while WuXi Biologics and Kelaiying represent the pharmaceutical sector's output capabilities [26][27]. - Future trends indicate a broadening of applications into new areas such as biobased textiles and environmental remediation [27].